Pages that link to "Q33274853"

The following pages link to Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis (Q33274853):

Displaying 36 items.

• Long-term course and effectiveness of combination therapy in Alzheimer disease (Q24642161) (← links)
• Effects of Music on Agitation in Dementia: A Meta-Analysis (Q30402566) (← links)
• Cellular bioenergetics as a target for obesity therapy (Q33894407) (← links)
• Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice (Q33938047) (← links)
• Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? (Q34121565) (← links)
• Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies (Q34156798) (← links)
• Current and emerging drug treatment options for Alzheimer's disease: a systematic review. (Q34222721) (← links)
• Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease (Q34297733) (← links)
• FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease (Q34415342) (← links)
• Altered Actions of Memantine and NMDA-Induced Currents in a New Grid2-Deleted Mouse Line (Q34774760) (← links)
• Preventing loss of independence through exercise (PLIÉ): a pilot clinical trial in older adults with dementia (Q35074465) (← links)
• The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer's Disease (Q35965628) (← links)
• Management of patients with Alzheimer's disease: pharmacological treatment and quality of life (Q36515587) (← links)
• Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease (Q36788139) (← links)
• Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis (Q36897422) (← links)
• Function and clinical meaningfulness of treatments for mild Alzheimer's disease (Q36934148) (← links)
• An update on huperzine A as a treatment for Alzheimer's disease (Q37071192) (← links)
• Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease (Q37337050) (← links)
• Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis (Q37863755) (← links)
• Predictors of decline in walking ability in community-dwelling Alzheimer's disease patients: Results from the 4-years prospective REAL.FR study (Q37690738) (← links)
• Use of Psychostimulants in Patients with Dementia (Q37782195) (← links)
• Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin (Q37959556) (← links)
• Education and use of dementia drugs: a register-based study of over 600,000 older people (Q39823141) (← links)
• Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China (Q41652286) (← links)
• Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons (Q42435326) (← links)
• Concomitant use of anti-dementia drugs with psychotropic drugs in Norway--a population-based study (Q43719682) (← links)
• Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. (Q45972237) (← links)
• Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients (Q46353578) (← links)
• Randomized controlled trial of a six-week spiritual reminiscence intervention on hope, life satisfaction, and spiritual well-being in elderly with mild and moderate dementia (Q47568880) (← links)
• Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures (Q48125798) (← links)
• Ten years of cholinesterase inhibitors. (Q53399979) (← links)
• Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease. (Q53427766) (← links)
• Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease (Q64255298) (← links)
• Therapeutic strategies for Alzheimer's disease (Q81527536) (← links)
• Concomitant Use of Cholinesterase Inhibitors and Anticholinergics: Prevalence and Outcomes (Q82545111) (← links)
• Spouse and adult child differences in caregiving burden (Q85361523) (← links)